77 related articles for article (PubMed ID: 23108380)
21. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.
Davis T; Kennedy C; Chiew YE; Clarke CL; deFazio A
Clin Cancer Res; 2000 Nov; 6(11):4334-42. PubMed ID: 11106251
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
23. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
24. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
27. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
29. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
Xu WS; Perez G; Ngo L; Gui CY; Marks PA
Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
[TBL] [Abstract][Full Text] [Related]
30. Microfluidic chip with integrated electrical cell-impedance sensing for monitoring single cancer cell migration in three-dimensional matrixes.
Nguyen TA; Yin TI; Reyes D; Urban GA
Anal Chem; 2013 Nov; 85(22):11068-76. PubMed ID: 24117341
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
33. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
34. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
35. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer.
Park SY; Jun JA; Jeong KJ; Heo HJ; Sohn JS; Lee HY; Park CG; Kang J
Oncol Rep; 2011 Jun; 25(6):1677-81. PubMed ID: 21455583
[TBL] [Abstract][Full Text] [Related]
37. Silicon nanograss based impedance biosensor for label free detection of rare metastatic cells among primary cancerous colon cells, suitable for more accurate cancer staging.
Abdolahad M; Shashaani H; Janmaleki M; Mohajerzadeh S
Biosens Bioelectron; 2014 Sep; 59():151-9. PubMed ID: 24727600
[TBL] [Abstract][Full Text] [Related]
38. Wavelet-based multiscale analysis of bioimpedance data measured by electric cell-substrate impedance sensing for classification of cancerous and normal cells.
Das D; Shiladitya K; Biswas K; Dutta PK; Parekh A; Mandal M; Das S
Phys Rev E Stat Nonlin Soft Matter Phys; 2015 Dec; 92(6):062702. PubMed ID: 26764722
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of nano-scale coatings on gold electrodes for bioimpedance studies of breast cancer cells.
Srinivasaraghavan V; Strobl J; Wang D; Heflin JR; Agah M
Biomed Microdevices; 2014 Oct; 16(5):689-96. PubMed ID: 24867593
[TBL] [Abstract][Full Text] [Related]
40. Design and validation of a multi-electrode bioimpedance system for enhancing spatial resolution of cellular impedance studies.
Alexander FA; Celestin M; Price DT; Nanjundan M; Bhansali S
Analyst; 2013 Jul; 138(13):3728-34. PubMed ID: 23689543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
